Dr. Whisenant is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1950 Circle of Hope
Clinic 1a
Salt Lake City, UT 84112Phone+1 801-585-0100Fax+1 801-585-7902
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2002 - 2005
University of ColoradoResidency, Internal Medicine, 1998 - 2001- University of California San Francisco School of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2001 - Present
UT State Medical License 2005 - 2026
CO State Medical License 2000 - 2001- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
- Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma Start of enrollment: 2018 Apr 11
- Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy Start of enrollment: 2019 Dec 15
Publications & Presentations
PubMed
- 208 citationsFinal Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.Andrew X. Zhu, Teresa Macarulla, Milind Javle, R. Kate Kelley, Sam J. Lubner
JAMA Oncology. 2021-11-01 - 517 citationsIvosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyGhassan K. Abou-Alfa, Teresa Macarulla, Milind Javle, Robin Kate Kelley, Sam J. Lubner
The Lancet. Oncology. 2020-06-01 - 20 citationsPublisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancersConan G. Kinsey, Soledad A. Camolotto, Amelie M. Boespflug, Katrin P. Guillen, Mona Foth
Nature Medicine. 2019-05-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
